The global race is on for a vaccine to combat the coronavirus, but the question is: Who will be included?

To date, several companies have reached Phase 3 trials for an experimental vaccine — including Moderna, Pfizer, AstraZeneca and CanSino. AstraZeneca recently announced a pause in its process to check a complication with one participant. Despite this setback, the early results are encouraging.

Yet these trials have not met an important challenge: recruiting an appropriately diverse group of participants — even though Covid-19 has taken a disproportionate toll on communities of color and on Black Americans in particular.

Drugmakers approved for Phase 3 trials have been slow to report the breakdown of participants. But Dr. Francis Collins, director of the National Institutes of Health, told CNN that Moderna …continued .
[Source: New York Times]